Navigation Links
IU researchers: Chemotherapy alters brain tissue in breast cancer patients
Date:9/29/2010

INDIANAPOLIS -- Researchers at the Indiana University Melvin and Bren Simon Cancer Center have published the first report using imaging to show that changes in brain tissue can occur in breast cancer patients undergoing chemotherapy.

The cognitive effects of chemotherapy, often referred to as "chemobrain," have been known for years. However, the IU research is the first to use brain imaging to study women with breast cancer before and after treatment, showing that chemotherapy can affect gray matter. The researchers reported their findings in the October 2010 edition of Breast Cancer Research and Treatment.

"This is the first prospective study," said Andrew Saykin, Psy.D., director of the Indiana University Center for Neuroimaging and a researcher at the IU Simon Cancer Center. "These analyses, led by Brenna McDonald, suggest an anatomic basis for the cognitive complaints and performance changes seen in patients. Memory and executive functions like multi-tasking and processing speed are the most typically affected functions and these are handled by the brain regions where we detected gray matter changes."

Dr. Saykin, who is Raymond C. Beeler Professor of Radiology at the IU School of Medicine, and colleagues studied structural MRI scans of the brain obtained on breast cancer patients and healthy controls. The scans were taken after surgery, but before radiation or chemotherapy, to give the researchers a baseline. Scans were then repeated one month and one year after chemotherapy was completed.

The researchers found gray matter changes were most prominent in the areas of the brain that are consistent with cognitive dysfunction during and shortly after chemotherapy. Gray matter density in most women improved a year after chemotherapy ended.

For many patients, Dr. Saykin said, the effects are subtle. However, they can be more pronounced for others. Although relatively rare, some patients -- often middle-aged women -- are so affected that they are never able to return to work. More commonly, women will still be able to work and multi-task, but it may be more difficult to do so.

The study focused on 17 breast cancer patients treated with chemotherapy after surgery, 12 women with breast cancer who did not undergo chemotherapy after surgery, and 18 women without breast cancer.

"We hope there will be more prospective studies to follow so that the cause of these changes in cancer patients can be better understood," Dr. Saykin said.

Dr. Saykin and his colleagues started their research at Dartmouth Medical School before finishing the data analyses at IU. A new, independent sample is now being studied at the IU Simon Cancer Center to replicate and further investigate this problem affecting many cancer patients.


'/>"/>

Contact: Michael Schug
maschug@iupui.edu
317-278-0953
Indiana University School of Medicine
Source:Eurekalert  

Related medicine news :

1. New developments in nanotechnology tackle the 2 biggest problems associated with chemotherapy
2. Roche/Genentech/Chugais Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer
3. Scientists identify microRNA as possible cause of chemotherapy resistance
4. Study evaluates costs and benefits of new chemotherapy drugs
5. Researchers find new chemotherapy combination shows promise in endometrial cancer
6. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
7. Recommended Dental Care for Chemotherapy Patients -- Advice from Steven McConnell, DDS
8. Pregnant women can receive breast cancer chemotherapy without endangering health of their babies
9. Making Your Way Through the Fog of Chemotherapy
10. Interruption of Menstrual Cycle by Chemotherapy Associated with Improved Survival in Early Breast Cancer
11. Ancient Chinese herbal recipe eases side effects of chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
IU researchers: Chemotherapy alters brain tissue in breast cancer patients
(Date:3/28/2017)... ... 2017 , ... Via Oncology, the leading provider of oncology ... public-facing tool for analyzing the costs of various drug regimens in cancer care. ... patients, providers, insurers and pharmaceutical companies about the estimated costs of treatment options. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... announces today that the University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® ... Western Pennsylvania. , The program, developed in association with efforts by the American ...
(Date:3/28/2017)... ... ... Usually, the impending arrival of warmer weather means the gleeful banishment of ... chin, this means more anxiety than elation. The cosmetic dermatology experts at Cosmetic Laser ... chin is undesirable,” Dr. Goldman said, “but it seems doubly so when the fat ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, ... to ensuring high-quality results and maintaining GMP and USP compliance. In a new ... accordance with GMP requirements " these requirements are explained. The challenge is ...
(Date:3/28/2017)... ... 2017 , ... Qualidigm , the mission-driven national healthcare ... new, more expansive office space in order to accommodate its growing number of ... building in Wethersfield, Conn. located at 936 Silas Deane Highway and immediately began ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Market leading ... announced a partnership with premium news content provider ... companies to extract key insights from Dow Jones ... technology. The Linguamatics I2E platform is ... global pharmaceutical companies. The Linguamatics-Dow Jones partnership helps ...
(Date:3/28/2017)... , March 28, 2017  CASI Pharmaceuticals, ... innovative therapeutics addressing cancer and other unmet medical ... American Association for Cancer Research annual meeting.  The ... is entitled "Evaluation of ENMD-2076 in Combination ... the second poster to be presented on April ...
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
Breaking Medicine Technology: